Designing phase 0 cancer clinical trials. - Wikidata - awgldk - TriplyDB

Designing phase 0 cancer clinical trials.

Designing phase 0 cancer clinical trials.

http://www.wikidata.org/entity/Q36732115

about

Unveiling changes in the landscape of patient populations in cancer early drug development Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma What are the endpoints of therapy for acute leukemias? Old definitions and new challenges.Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668 Phase 0 trials: expediting the development of chemoprevention agents.Phase 0 clinical trials in oncology new drug development.Phase 0 Workshop at the 20th EORTC-NCI-AACR Symposium, Geneva.Phase 0 clinical trials: towards a more complete ethics critique.Normal tissue protection for improving radiotherapy: Where are the Gaps?New considerations in the design of clinical trials for the treatment of acute leukemia.Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient Early-phase development of cancer prevention agents: challenges and opportunities Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.Phase 0 clinical studies in oncology.The statistics of phase 0 trials.Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.Drug therapy of cancer.Phase zero trials: a novel approach in drug development process.Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development.Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention.FGFR-TACC gene fusions in human glioma.Toward Personalized Targeted Therapeutics: An Overview.Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor.EORTC trial 11001: distribution of two 10B-compounds in patients with squamous cell carcinoma of head and neck, a translational research/phase 1 trial.State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research-NCI Strategic Workshop Highlights of Discussion Report.Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors.Brain Tumor Clinical Trials: Perspective 2014.Prostate cancer chemoprevention by natural agents: Clinical evidence and potential implications Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2

P2860

Q28073826-2CEFC9FB-CC76-4526-8A25-6DC52B33F1F9 Q28537857-36774A78-1CDA-4278-A030-F5968BEFC16B Q33775647-0DF3E0E6-27CE-46A8-905A-399C31474BC7 Q33985780-4B75FC27-378F-4982-979E-475034329281 Q34316288-F8DFBCB7-8BB9-4034-AAA8-435CBD4AEF4C Q34701702-0CA177A7-266E-497D-B6AE-180A2A9F8722 Q34802510-1367471B-22CC-497D-986F-1F804C6857B4 Q34941964-AD6373E2-1F3E-4784-A30F-91E334BA9B1A Q35602195-2498C0F1-D5D6-4984-83A9-D20B2DB6EEF8 Q35883053-F74F2178-E7AE-4370-B7AF-3D6E4A8D3AC2 Q36137870-64F8AF65-7DAB-4576-ACE7-D74676AA4E75 Q36641721-85357FC7-86C8-41BD-B335-FECD49B0A8EF Q36732058-9F6D0C5B-4F1C-43EB-AF24-B73C5DB672E4 Q36853927-7A15FB84-1BF9-4D77-B005-68D4CCA3AD08 Q37337123-51F51964-6EDE-4D24-9DE2-88CCA8C8C477 Q37358487-211D141F-1756-482B-B0FF-2CD59A219EF6 Q37515513-7F8E579D-A5FA-4F08-945E-2CF289593336 Q37552670-F4D4A581-0A96-49F5-8376-51144ACBA2A3 Q37845248-5CB90472-0B2D-4550-9AD9-0BD6471BBB39 Q38119561-CA65EC9C-EF69-4B04-ACF8-BF57F3A92425 Q38818203-FF5B462E-9C60-4A1A-95BD-B2325699E563 Q38843584-2CDECA51-4431-43F8-AEE2-37C31A9C78C0 Q39010445-7E55CC1B-6C0A-425C-8AE3-DD7B4C1A27EC Q39044141-DA557896-9357-4660-961B-9304D41EF30A Q39842254-3A58C008-60F1-4D75-8559-4F863AD58C52 Q45929421-D5BBFDF5-3D8D-49ED-BABA-805685B39D15 Q47217032-4003BE0C-A348-46D6-989E-0F6A9FAFBE63 Q50422614-84781BFD-737C-4F23-A993-439EE038D0F1 Q52151988-2AEA8B7B-A405-461A-B200-5C30953B4B22 Q57112620-6276396A-6287-4625-BE9D-796C6AFD29D4 Q57266579-892CF04E-2728-468F-8B5D-92E9EA530C70

P2860

Designing phase 0 cancer clinical trials.

http://www.wikidata.org/entity/Q36732115

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Designing phase 0 cancer clinical trials.

@ast

Designing phase 0 cancer clinical trials.

@en

type

label

Designing phase 0 cancer clinical trials.

@ast

Designing phase 0 cancer clinical trials.

@en

prefLabel

Designing phase 0 cancer clinical trials.

@ast

Designing phase 0 cancer clinical trials.

@en

P1433

Q36732115-61CB457E-14F6-4DE1-A0DA-87928E75C3BA

P1476

Q36732115-23D36BFE-AF89-468D-81D4-11F192AF731F

P2093

Q36732115-05D6ECB0-641F-4D94-A62B-553CAD5ECD47

Q36732115-20D5AFF4-77E3-4B08-AD17-C3E9E919197B

Q36732115-28DB5572-1D76-45C0-8DDC-F2164B1C864F

Q36732115-2B8AC458-57EA-420D-9CC0-E516BECDA29C

Q36732115-34BEEC95-B1D0-44C6-968D-75354C7AA8E4

Q36732115-4DEC444D-2E33-4E52-BF3F-BCC9EE5ABAF2

Q36732115-6944E116-0E69-4551-92FA-F1C027D9EDB4

Q36732115-6D66C83E-DE6B-4040-B40F-130F7AE7F19C

Q36732115-8BD1D6EA-05EF-4639-92BF-D9A54AF82B33

Q36732115-96DB1B45-2D07-4B1A-BC31-566673C4C50B

P2860

Q36732115-226D55C2-949F-4D80-B621-69C0906F5CA7

Q36732115-340C3A05-FCF2-4030-B799-9741CDFB1E03

Q36732115-48235699-1FF2-48E6-A5C3-AB63BC3466C2

Q36732115-5578427E-0AB7-4DB9-8484-219868A80656

Q36732115-6F657E55-319E-4987-8547-84DAD8D1A46D

Q36732115-8EA7FE27-79DF-4FE8-8443-D5650BDD7594

Q36732115-B4B50721-47C7-489A-94E8-1D21F30D164A

Q36732115-B6FD5B38-B1D7-43B8-9FFD-6248D07B50B2

Q36732115-C04A00E7-110A-4709-9614-D88C0233A3C9

Q36732115-C718A53A-2F4A-4E3D-A8E8-556736F9B045

P304

Q36732115-18E1583C-3941-406F-887C-BE904BB3FEEF

P31

Q36732115-3E7F0223-5F65-4668-80AE-E64960E53EDC

P356

Q36732115-51A56DF9-BC90-46E7-AF79-071679E3C009

P407

Q36732115-0231328D-FD84-4E79-978A-17B212CFF109

P433

Q36732115-DEC46DE1-9BDC-43DB-9E55-2ADF0502E67A

P478

Q36732115-1F58B9D7-00ED-482D-82C3-997B2F4F59C9

P577

Q36732115-60563EBD-102E-4DF6-8B2A-02E863FF5832

P5875

Q36732115-3FBBFC85-C719-410B-AA60-C41B840CC485

P698

Q36732115-46518E21-86C3-4E28-8E70-42A827C5791A

P932

Q36732115-E60A2BD7-65BD-4003-A4C9-D147E869700A

P356

1078-0432.CCR-07-4560

P1433

Clinical Cancer Research

P1476

Designing phase 0 cancer clinical trials.

@en

P2093

Alice Chen

http://www.w3.org/2001/XMLSchema#string

Anthony J Murgo

http://www.w3.org/2001/XMLSchema#string

James H Doroshow

http://www.w3.org/2001/XMLSchema#string

Jerry Collins

http://www.w3.org/2001/XMLSchema#string

Jiuping Ji

http://www.w3.org/2001/XMLSchema#string

Joseph E Tomaszewski

http://www.w3.org/2001/XMLSchema#string

Larry Rubinstein

http://www.w3.org/2001/XMLSchema#string

Lee Helman

http://www.w3.org/2001/XMLSchema#string

Martin Gutierrez

http://www.w3.org/2001/XMLSchema#string

Melinda Hollingshead

http://www.w3.org/2001/XMLSchema#string

P2860

Can the pharmaceutical industry reduce attrition rates?

Receptor imaging in oncology by means of nuclear medicine: current status.

The progress and promise of molecular imaging probes in oncologic drug development.

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.

Innovative early development regulatory approaches: expIND, expCTA, microdosing.

Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.

The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.

Phase 0 trials: an industry perspective.

Imaging and other biomarkers in early clinical studies: one step at a time or re-engineering drug development?

Phase 0 trials: are they ethically challenged?

P304

3675-3682

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-07-4560

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5296316

http://www.w3.org/2001/XMLSchema#string

P698

18559582

http://www.w3.org/2001/XMLSchema#string

P932

2435428

http://www.w3.org/2001/XMLSchema#string